Mid-America Apartment Communities(MAA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAA Mid-America Apartment Communities

Pre-Market Trading 11-15 04:22:37 EST

157.37

-3.97

-2.46%

High161.43	Low157.22	Vol617.59K
Open161.18	D1 Closing161.34	Amplitude2.61%
Mkt Cap18.39B	Tradable Cap18.22B	Total Shares116.88M
T/O97.86M	T/O Rate0.53%	Tradable Shares115.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MAA","market":"US","secType":"STK","nameCN":"Mid-America Apartment Communities","latestPrice":157.37,"timestamp":1731618000000,"preClose":161.34,"halted":0,"volume":617588,"delay":0,"floatShares":115804548,"shares":116880291,"eps":4.432946,"marketStatus":"Pre-Market Trading","change":-3.97,"latestTime":"11-15 04:22:37 EST","open":161.18,"high":161.43,"low":157.22,"amount":97859937.4194,"amplitude":0.026094,"askPrice":173.89,"askSize":100,"bidPrice":137.18,"bidSize":100,"shortable":3,"etf":0,"ttmEps":4.432946,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1731681000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":157.37,"dividendRate":0.036919,"postHourTrading":{"tag":"盘后","latestPrice":157.37,"preClose":157.37,"latestTime":"18:18 EST","volume":26307,"amount":4139900.28,"timestamp":1731626326191},"volumeRatio":0.9161495936065052,"impliedVol":0.2771,"impliedVolPercentile":0.757},"requestUrl":"/m/hq/s/MAA/wiki","defaultTab":"wiki","newsList":[{"id":"2483337334","title":"Ascendis Pharma Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483337334","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483337334?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:01","pubTimestamp":1731618060,"startTime":"0","endTime":"0","summary":"–YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of 8.5 million in Q3 – TransCon CNP NDA submission for achondroplasia planned for Q1 2025 fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981569/0/en/Ascendis-Pharma-Reports-Third-Quarter-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MAA","BK4561","BK4585","BK4215","ET","BK4144","BK4581","PROC","BK4007","BK4590"],"gpt_icon":0},{"id":"2483381961","title":"CHMP issues positive recommendation for approval of lecanemab in the EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2483381961","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483381961?lang=en_us&edition=fundamental","pubTime":"2024-11-15 01:00","pubTimestamp":1731603600,"startTime":"0","endTime":"0","summary":"STOCKHOLM, Nov. 14, 2024 /PRNewswire/ -- BioArctic AB   today announces that EMA's Committee for Medicinal Products for Human Use  has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization application  for lecanemab as treatment of Alzheimer's disease. The recommendation applies to the treatment of early Alzheimer's disease in adult patients that are apolipoprotein E ε4  heterozygotes or non-carriers.The CHMP recommendation for the European Commission to approve lecanemab follows Eisai's request for a re-examination of the CHMP's earlier negative recommendation. A decision from the European Commission is expected within 67 days.Lecanemab is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, United Arab Emirates and Great Britain for the treatment of MCI due to AD and mild AD dementia. Lecanemab's approvals in these countries, as well as the CHMP's opinion, were primarily based on Phase 3 data from Eisai's global Clarity AD clini","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hdJh9LqLvU6kukp1u7GyLg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/d71fdf0a9a58ad61dcb8c489cc42322f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hdJh9LqLvU6kukp1u7GyLg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/d71fdf0a9a58ad61dcb8c489cc42322f"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/chmp-issues-positive-recommendation-approval-170000789.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chmp-issues-positive-recommendation-approval-170000789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MAA","BK4087","BK4585","BRCTF","CHMP","BK4156","MCI","BK4588","BK4139","BK4215"],"gpt_icon":0},{"id":"2483865393","title":"Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2483865393","media":"GlobeNewswire","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483865393?lang=en_us&edition=fundamental","pubTime":"2024-11-15 00:23","pubTimestamp":1731601380,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., Nov.  14, 2024  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981433/0/en/Eisai-Receives-Positive-Opinion-from-the-CHMP-in-the-European-Union-for-Lecanemab-in-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4087","BK4215","BK4585","CHMP","MAA","BK4588","CDR"],"gpt_icon":0},{"id":"2483755418","title":"Press Release: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483755418","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483755418?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:50","pubTimestamp":1731585000,"startTime":"0","endTime":"0","summary":"Company to host conference call and webcast today at 8:30 a.m. EST. CARMIEL, Israel, Nov. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2024, and provided a business and clinical update.\"We are pleased to report that all eight cohorts of our phase I first-in-human study of PRX-115, our recombinant uricase candidate being developed for the treatment of uncontrolled gout, are now complete,\" said Dror Bashan, Protalix's President and Chief Executive Officer. \"Preliminary results from this study, being presented today and this week in a late-breaking poster at ACR Convergence 2024, are encouraging and demonstrate the potential of PRX-115 to be a promising uric-acid lowering treatment option for individuals ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","IE00B19Z3B42.SGD","BK4181","LU1066053197.SGD","LU0306806265.USD","ACR","BK4555","LU0868494617.USD","SG9999001176.SGD","PK","LU0306807586.USD","IE000M9KFDE8.USD","BK4215","SG9999001176.USD","BK4110","BK4139","LU1883839398.USD","SG9999013999.USD","IE00BLSP4239.USD","LU0321505868.SGD","SG9999003800.SGD","LU0289739699.SGD","BK4585","LU0234572021.USD","LU0122379950.USD","R","BK4218","PFE","PLX","BK4022","LU0170899867.USD","BK4588","BK4232","LU0225771236.USD","BK4533","BK4592","LU1066051498.USD","BK4534","LU0058720904.USD","MAA","LU0321505439.SGD","LU1894683264.USD","SGXZ57979304.SGD","TM","BK4581","SG9999011175.SGD","03160","LU1023059063.AUD","SG9999002224.SGD","LU1057294990.SGD"],"gpt_icon":1},{"id":"2483866634","title":"Mid-America Apartment Communities Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2483866634","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483866634?lang=en_us&edition=fundamental","pubTime":"2024-11-14 06:11","pubTimestamp":1731535860,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Mid-America Apartment Communities Inc.  inched 0.99% higher to $161.34 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 0.02% to 5,985.38 and the Dow Jones Industrial Average  rising 0.11% to 43,958.19.Mid-America Apartment Communities Inc. closed $6.05 short of its 52-week high , which the company reached on September 16th.The stock underperformed when compared to some of its competitors Wednesday, as Avalonbay Communities Inc.  rose 1.26% to $233.11, Equity Residential  rose 2.18% to $74.64, and UDR Inc.  rose 2.08% to $45.19.Trading volume  remained 47,826 below its 50-day average volume of 710,988.Data source: Dow Jones Market Data, FactSet. Data compiled November 13, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones New","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAA"],"gpt_icon":0},{"id":"2483865388","title":"Alvotech Reports Financial Results for the First Nine Months of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483865388","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483865388?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531900,"startTime":"0","endTime":"0","summary":"Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 million. Product revenues in the first nine months of 2024 increased over four-fold compared to the same period last year, to $128 million, with Q3 product revenues contributing $62 million. License and other revenues for the first nine months of 2024 increased by $203 from the same period last year, to $211 million, with Q3 license and other revenues contributing $41 million. Adjusted EBITDA was $87 million in the first nine months of 2024, compared to negative  million for the same period last year, with Q3 adjusted EBITDA contributing $23 million. Marketing applications were accepted in Europe for biosimilar candidates to Prolia/Xgeva  and Simponi  and Alvotech initiated a confirmatory clinical study for AVT16, a biosimilar candidate to Entyvio . Alvotech announced the initiation of a confirmatory patient study for AVT16, a pr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TBXyZWnxswZ8Dw4HDKF8NQ--~B/aD0zNjQ7dz0xMDQ1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/8a0f73734c0720ca8ced92018fd212e7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TBXyZWnxswZ8Dw4HDKF8NQ--~B/aD0zNjQ7dz0xMDQ1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/8a0f73734c0720ca8ced92018fd212e7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alvotech-reports-financial-results-first-210500240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4555","FR","BK4585","BK4215","BK4099","MAA","ALVOW","F","BK4171","BK4139","ALVO","BK4588","BK4574","BK4156","BK4224","BK4516"],"gpt_icon":1},{"id":"2483120830","title":"Baird Adjusts Price Target on Mid-America Apartment Communities to $160 From $158, Maintains Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2483120830","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483120830?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:33","pubTimestamp":1731508404,"startTime":"0","endTime":"0","summary":"Mid-America Apartment Communities (MAA) has an average outperform rating and a price target range of $124 to $187, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAA"],"gpt_icon":0},{"id":"2483007009","title":"MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483007009","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483007009?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:00","pubTimestamp":1731502800,"startTime":"0","endTime":"0","summary":"Received 3 Rare Pediatric Disease Designations (RPDD) from FDA for each of 3 potential therapies for 3 different rare inherited retinopathies including AAV-AIPL1 Agreed on pathway with MHRA for Market","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/13/2980218/0/en/MeiraGTx-Announces-Third-Quarter-2024-Financial-and-Operational-Results-and-Recent-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","BK4581","IE00BJT1NW94.SGD","BK4534","LU1221951129.SGD","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","LU1066051811.HKD","MAA","IE00BJJMRZ35.SGD","LU1023059063.AUD","IE000M9KFDE8.USD","LU0203347892.USD","IE0002270589.USD","LU0466842654.USD","LU1066051498.USD","LU0320765646.SGD","LU1196500208.SGD","LU1032466523.USD","IE00BGHQF631.EUR","LU0345770308.USD","LCA","BK4592","IE00B19Z3B42.SGD","LU0234570918.USD","IE00B42XCP33.USD","BK4533","JNJ","BK4007","LU0234572021.USD","BK4504","LU0345769128.USD","IE00BDGV0183.EUR","IE0034235303.USD","BK4585","LU0345770993.USD","LU1032955483.USD","LU0122379950.USD","LU1059921491.USD","LU1057294990.SGD","LU1066051225.USD","LU0912757837.SGD","IE00B4R5TH58.HKD","IE00BVYPNW00.USD","LU0795875086.SGD","IE00B3PB1722.GBP","LU0889566641.SGD","IE0002141913.USD","BK4550","LU0640476718.USD"],"gpt_icon":0},{"id":"2483075008","title":"X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483075008","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483075008?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:07","pubTimestamp":1731496020,"startTime":"0","endTime":"0","summary":"Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced today Pivotal Phase 3 trial of mavorixafor in CN on track to fully enroll in mid-2025 U.S. launch of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/13/2980044/0/en/X4-Pharmaceuticals-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CN","BK4588","BK4215","BK4585","MAA"],"gpt_icon":0},{"id":"2482088299","title":"Bank of America Securities Sticks to Their Buy Rating for Mid-America Apartment (MAA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482088299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482088299?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:18","pubTimestamp":1731421113,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Joshua Dennerlein maintained a Buy rating on Mid-America Apartment (MAA – Research Report) today. The company’s ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-buy-rating-for-mid-america-apartment-maa-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":"4f39c97a1ea1fef5140865d016da6efe","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-buy-rating-for-mid-america-apartment-maa-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAA"],"gpt_icon":0},{"id":"2482088395","title":"Savara Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482088395","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482088395?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:05","pubTimestamp":1731416700,"startTime":"0","endTime":"0","summary":"Recently Completed Pre-BLA Meeting with FDA for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis . Company Plans to Initiate Biologics License Application  Rolling Submission by End of Year. With ~$219M in Cash and Short-Term Investments, the Company Believes it is Sufficiently Capitalized through 2Q 2027. LANGHORNE, Pa., November 12, 2024----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2024 and provided a business update.Savara's net loss for the third quarter of 2024 was $24.2 million, or $ per share, compared with a net loss of $16.6 million, or $ per share, for the third quarter of 2023.General and administrative expenses increased by $1.9 million, or 45.0%, to $6.0 million for the three months ended September 30, 2024 from $4","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oPE5lOx1p22d3Opl38N3zg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0d2ac8a61f534f5f44758b269c852276","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oPE5lOx1p22d3Opl38N3zg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0d2ac8a61f534f5f44758b269c852276"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-reports-third-quarter-2024-130500652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVRA","BK4215","MAA","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2482706489","title":"ImmunityBio Reports Third-Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2482706489","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482706489?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:15","pubTimestamp":1731413700,"startTime":"0","endTime":"0","summary":"CULVER CITY, Calif., November 12, 2024----ImmunityBio, Inc.  today announced its financial results for the third-quarter ended September 30, 2024.ANKTIVA received a J-code  in October 2024, effective January 1, 2025.ANKTIVA  is now widely accessible to patients through commercial and government insurance programs . ImmunityBio has secured coverage for over 200 million medical lives through medical reimbursement policies.ImmunityBio achieved a net product revenue of approximately $6.0 million during the three months ended September 30, 2024, surpassing net product revenue of $1.0 million in the prior quarter and analyst estimates.ImmunityBio has extended the shelf life of ANKTIVA from two years to three years, with over 125,000 doses, providing ample product for the market and for clinical trials.ImmunityBio intends to submit to the European Medicines Agency  an MAA for ANKTIVA in the European Union  in Q4 2024, covering 30 countries, including 27 in the EU and 3 in the European Economi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SyeXsVh5hHdW.EB6zUmowA--~B/aD0yNzA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6074e80700868a2fb12897fc9d782da2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SyeXsVh5hHdW.EB6zUmowA--~B/aD0yNzA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6074e80700868a2fb12897fc9d782da2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunitybio-reports-third-quarter-2024-121500066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MAA","IBRX","BK4585","BK4215","WRD","BK4139","BK4156","BK4588"],"gpt_icon":0},{"id":"2482703872","title":"Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2482703872","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482703872?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:00","pubTimestamp":1731412800,"startTime":"0","endTime":"0","summary":"- Reported positive topline data from pivotal Phase 3 SAPPHIRE trial evaluating apitegromab in patients with Spinal Muscular Atrophy , achieving primary endpoint. - On track to submit a U.S. Biologics License Application  and European Union marketing authorisation application  in 1Q 2025. - Successful completion of upsized $345 million public offering to fund planned commercial launch in SMA and continue to advance priority programs. Dr. Backstrom continued, \"The robust results from SAPPHIRE also reinforce the broader potential of our selective myostatin inhibition strategy across our pipeline, with potential readthrough to our cardiometabolic program as we evaluate apitegromab in obesity in our Phase 2 EMBRAZE proof-of-concept trial. We were pleased to announce in September that the EMBRAZE trial is fully enrolled, and we expect to report initial data in the second quarter of next year.\". Reported positive topline data from Phase 3 SAPPHIRE clinical trial. The study achieved its prima","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/y9xKn0pfX6efCrojkUMqNg--~B/aD0yMDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4bf222bf2e9676a01bcbffe9ee233be2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/y9xKn0pfX6efCrojkUMqNg--~B/aD0yMDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4bf222bf2e9676a01bcbffe9ee233be2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scholar-rock-reports-third-quarter-120000034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PRGS","BK4107","BK4215","BK4097","L","WRD","BK4139","BK4585","MAA","SRRK","LU2065732104.USD","LU0053666078.USD","BK4588"],"gpt_icon":0},{"id":"2482977749","title":"SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2482977749","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482977749?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:30","pubTimestamp":1731411000,"startTime":"0","endTime":"0","summary":"– Achieved $49.3 million in OGSIVEO (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2978842/0/en/SpringWorks-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","LENZ","BK4215","BK4139","BK4585","MAA","CTOS","BK4588"],"gpt_icon":0},{"id":"2482708295","title":"KalVista Pharmaceuticals to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2482708295","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482708295?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:30","pubTimestamp":1731411000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass. & SALISBURY, England, November 12, 2024----KalVista Pharmaceuticals, Inc. , today announced that the Company will participate in a fireside chat at each of the following investor conferences:. KalVista Pharmaceuticals, Inc. is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with significant unmet need. Sebetralstat, our novel, investigational candidate for the oral, on-demand treatment of hereditary angioedema, is under regulatory review by the U.S. FDA with a PDUFA goal date of June 17, 2025. In addition, we have completed marketing authorization application  submissions for sebetralstat to the European Medicines Agency as well as the United Kingdom, Switzerland, Australia, and Singapore, and we anticipate filing a MAA in Japan in late 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oBo1JPxcznrnmcig5bOv8w--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/9437d24101266d935fab4a5afc2ddd0b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oBo1JPxcznrnmcig5bOv8w--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/9437d24101266d935fab4a5afc2ddd0b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kalvista-pharmaceuticals-present-upcoming-investor-113000020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KALV","BK4585","BK4588","WRD","BK4215","BK4139","MAA"],"gpt_icon":0},{"id":"2482861764","title":"Mid-America Apartment Communities Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2482861764","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482861764?lang=en_us&edition=fundamental","pubTime":"2024-11-12 06:11","pubTimestamp":1731363060,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Mid-America Apartment Communities Inc.  inched 0.55% higher to $160.01 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 0.10% to 6,001.35 and the Dow Jones Industrial Average  rising 0.69% to 44,293.13.This was the stock's third consecutive day of gains.Mid-America Apartment Communities Inc. closed $7.38 below its 52-week high , which the company reached on September 16th.The stock outperformed some of its competitors Monday, as Avalonbay Communities Inc.  fell 0.66% to $232.21, Equity Residential  fell 0.04% to $73.50, and UDR Inc.  rose 0.36% to $44.64.Trading volume  remained 138,446 below its 50-day average volume of 703,484.Data source: Dow Jones Market Data, FactSet. Data compiled November 11, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published inde","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAA"],"gpt_icon":0},{"id":"2482658367","title":"Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2482658367","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482658367?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:05","pubTimestamp":1731359100,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., November 11, 2024----Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation at the 53rd Child Neurology Society  Annual Meeting of safety data from its prior Phase 3 ATTeST  clinical trial. The objective of the data analysis was to evaluate treatment-emergent adverse events  in patients with Ataxia-Telangiectasia (A-T) treated with the company’s lead asset, EryDex , for one year compared to placebo control.Key findings reported in the poster presentation, titled Treatment-Emergent Adverse Events  in Children With Ataxia-Telangiectasia Treated for One Year With Intra-Erythrocyte Dexamethasone Sodium Phosphate , include:. EryDex treatment was generally well tolerated with most TEAEs being mild to moderate and transient, and generally similar between EryDex- and placebo-treated patients.The Phase 3 NEAT trial is being ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.4gpwbEOwjMXPcRxtshgbA--~B/aD00NDI7dz0xMTIxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8f0798fc6f95c1a2cd7f76e8c08b0a52","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.4gpwbEOwjMXPcRxtshgbA--~B/aD00NDI7dz0xMTIxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8f0798fc6f95c1a2cd7f76e8c08b0a52"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quince-therapeutics-presents-safety-data-210500823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","QNCX","BK4588","LENZ","BK4135","BK4215","BK4139","BK4585","DSP","MAA","SPA","CNS"],"gpt_icon":1},{"id":"2482738684","title":"Piper Sandler Adjusts Price Target on Mid-America Apartment Communities to $170 From $165, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2482738684","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482738684?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:43","pubTimestamp":1731336218,"startTime":"0","endTime":"0","summary":"Mid-America Apartment Communities (MAA) has an average outperform rating and price targets ranging from $124 to $189, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAA"],"gpt_icon":0},{"id":"2482202043","title":"SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2482202043","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482202043?lang=en_us&edition=fundamental","pubTime":"2024-11-11 19:30","pubTimestamp":1731324600,"startTime":"0","endTime":"0","summary":"– Mirdametinib treatment demonstrated significant confirmed objective response rates and amanageable safety profile in adults and children with NF1-PN – – Patients achieved deep and durable reductions","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/11/2978166/0/en/SpringWorks-Therapeutics-Announces-Publication-of-the-Pivotal-Phase-2b-ReNeu-Trial-Evaluating-Mirdametinib-in-Adults-and-Children-with-NF1-PN-in-the-Journal-of-Clinical-Oncology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","BK4139","BK4585","LENZ","MAA","BK4588"],"gpt_icon":0},{"id":"2482478651","title":"Real estate stocks advance on rate cut, election results not-so-positive","url":"https://stock-news.laohu8.com/highlight/detail?id=2482478651","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482478651?lang=en_us&edition=fundamental","pubTime":"2024-11-10 01:00","pubTimestamp":1731171611,"startTime":"0","endTime":"0","summary":"EschCollection Real estate stocks gained on the back of a widely expected 25 basis point rate cut this week, but the election results failed to provide optimism. The Real Estate Select Sector SPDR Fun","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972371989/image_1972371989.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972371989/image_1972371989.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4269488-real-estate-stocks-advance-on-rate-cut-election-results-prove-negative","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["PSR","HST","REM","FREL","DLR","REG.AU","SPG","XLRE","CPT.AU","EXR","MAA","ESS.AU","EXR.AU","RWR","CFA.SI","AVB","UDR","BXP","IIPR","IRM","CPT","IYR","AMT","EQR","REG","NETL","CCI","USRT","NURE","REZ","JPRE","ROOF","DFAR","FRT","REIT","SCHH","SPRE","O","STWD","KBWY","FRI","VTR","KIM","DOC.AU","ESS","WY","INDS","DOC","EQR.AU","AMT.AU"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.maac.com","stockEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0309},{"period":"3month","weight":0.0296},{"period":"6month","weight":0.1425},{"period":"1year","weight":0.2778},{"period":"ytd","weight":0.1704}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MAA, an S&P 500 company, is a real estate investment trust (REIT) focused on delivering full-cycle and superior investment performance for shareholders through the ownership, management, acquisition, development and redevelopment of quality apartment communities primarily in the Southeast, Southwest and Mid-Atlantic regions of the United States. As of June 30, 2024, MAA had ownership interest in 103,614 apartment units, including communities currently in development, across 16 states and the District of Columbia.","yearOnYearQuotes":[{"month":1,"riseRate":0.633333,"avgChangeRate":-0.000504},{"month":2,"riseRate":0.451613,"avgChangeRate":-0.002597},{"month":3,"riseRate":0.612903,"avgChangeRate":0.017626},{"month":4,"riseRate":0.612903,"avgChangeRate":0.014339},{"month":5,"riseRate":0.645161,"avgChangeRate":0.014727},{"month":6,"riseRate":0.645161,"avgChangeRate":0.015102},{"month":7,"riseRate":0.516129,"avgChangeRate":0.014068},{"month":8,"riseRate":0.451613,"avgChangeRate":-0.000616},{"month":9,"riseRate":0.483871,"avgChangeRate":-0.005811},{"month":10,"riseRate":0.548387,"avgChangeRate":-0.008369},{"month":11,"riseRate":0.612903,"avgChangeRate":0.007453},{"month":12,"riseRate":0.7,"avgChangeRate":0.020519}],"exchange":"NYSE","name":"Mid-America Apartment Communities","nameEN":"Mid-America Apartment Communities"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mid-America Apartment Communities(MAA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mid-America Apartment Communities(MAA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mid-America Apartment Communities,MAA,Mid-America Apartment Communities股票,Mid-America Apartment Communities股票老虎,Mid-America Apartment Communities股票老虎国际,Mid-America Apartment Communities行情,Mid-America Apartment Communities股票行情,Mid-America Apartment Communities股价,Mid-America Apartment Communities股市,Mid-America Apartment Communities股票价格,Mid-America Apartment Communities股票交易,Mid-America Apartment Communities股票购买,Mid-America Apartment Communities股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mid-America Apartment Communities(MAA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mid-America Apartment Communities(MAA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction